Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial

• Published in: Cancer medicine (Malden, MA) MA), 2019-04, Vol.8 (4), p.1401-1405
• Main Authors: Egle, Alexander, Melchardt, Thomas, Obrtlíková, Petra, Smolej, Lukáš, Kozák, Tomáš, Steurer, Michael, Andel, Johannes, Burgstaller, Sonja, Mikušková, Eva, Gercheva, Liana, Nösslinger, Thomas, Papajík, Tomáš, Ladická, Miriam, Girschikofsky, Michael, Hrubiško, Mikuláš, Jäger, Ulrich, Voskova, Daniela, Pecherstorfer, Martin, Králiková, Eva, Burcoveanu, Christina, Spasov, Emil, Petzer, Andreas, Mihaylov, Georgi, Raynov, Julian, Oexle, Horst, Zabernigg, August, Flochová, Emília, Palášthy, Stanislav, Stehlíková, Olga, Doubek, Michael, Altenhofer, Petra, Weiss, Lukas, Magnes, Teresa, Pleyer, Lisa, Klingler, Anton, Mayer, Jiří, Greil, Richard
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; BMI; Body mass index; Bone marrow; Chronic lymphocytic leukemia; Clinical Cancer Research; CLL; Cytogenetics; Female; Humans; Immunotherapy; Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy; Leukemia, Lymphocytic, Chronic, B-Cell - mortality; Lymphatic leukemia; Lymphoma; maintenance; Maintenance Chemotherapy; Male; Medical prognosis; Middle Aged; Monoclonal antibodies; Obesity; Obesity - complications; Obesity - mortality; Original Research; Prognosis; Rituximab; Rituximab - administration & dosage; Rituximab - therapeutic use; Survival Analysis; Targeted cancer therapy; Treatment Outcome
• ISSN: 2045-7634; 2045-7634
• DOI: 10.1002/cam4.1980

No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL‐8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab‐containing induction treatment in first or second line that had achieved at least a PR. A randomization to rituximab maintenance treatment (375 mg/m2 q3 months for 2 years) vs observation was performed. In this cohort 22% of the patients (58/263) were classified as obese. The baseline response to induction treatment was inferior in obese patients with a lower CR rate (43.1% vs 60.5% in obese vs non‐obese, P = 0.018) and with a lower rate of patients achieving MRD negativity after chemoimmunotherapy induction treatment (19.6% vs 35.8%, P = 0.02). The PFS outcome of obese patients was significantly worse in the observation group of the trial (24 vs 39 months median PFS, P = 0.03). However, in the rituximab maintenance group the outcome for obese vs non‐obese was not different (P = 0.4). In summary, obesity was overall associated with a worse outcome of chemoimmunotherapy induction. However, rituximab maintenance treatment seems to be able to overcome this negative effect. We analyzed 263 patients from the AGMT CLL‐8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab‐containing induction treatment in first or second line that had achieved at least a PR. Obesity was overall associated with a worse outcome of chemoimmunotherapy induction.